Work Experience Work Experience 1976.1-1980.9 Department of Ophthalmology, Second Affiliated Hospital of China Medical University, Resident Physician 1983.9-1986.4 Department of Ophthalmology, PLA General Hospital, Resident Physician 1986.5-1991.3 Department of Ophthalmology, PLA General Hospital, Attending Physician 1991.4-2001.8 Department of Ophthalmology, PLA General Hospital, Chief Physician 2001.8-Present Eye Center, Peking University Third Hospital, Chief Physician 1998-2001.8 Department of Ophthalmology, PLA General Hospital, Department Director 2001.8-2010.3 Peking University Eye Center, Executive Deputy Director 2010.3-2014.9 Eye Center, Peking University Third Hospital, Director 2010.1-2012.12 Department of Ophthalmology, Peking University Health Science Center, Department Chair 1976.1-1980.9 Teaching and Research Section of Ophthalmology, Second Affiliated Hospital of China Medical University, Teaching Assistant 1991.4-Present Professor 1991.4-1999.2 Master's Degree Student Supervisor 1998.3-Present Doctoral Degree Student Supervisor Research Work 1) Independently developed a novel surgical technique, "Autologous Bruch's Membrane with Retinal Pigment Epithelium (RPE) Cell Transplantation for the Treatment of Age-Related Macular Degeneration (AMD)," involving surgery in the "forbidden zone" of fundus surgery — submacular and choroidal surgery. This work was awarded the Best Paper at the 2007 American Academy of Ophthalmology (AAO) Annual Meeting (the world's largest and most prestigious ophthalmology academic conference). The judging experts commented that the design of this technique and the entirely novel surgical approach were undoubtedly original work. During the meeting, the AAO newsroom issued press releases to more than 30 major media outlets in the United States, publicizing this significant technological breakthrough in the treatment of AMD. The related article was subsequently published in Investigative Ophthalmology & Visual Science (IOVS), a leading international ophthalmology journal. This represented a successful demonstration of China's latest achievements in ophthalmology on the international stage. 2) Established an ophthalmic genetic disease diagnosis and consultation platform. Using an independently developed "hereditary eye disease gene diagnostic chip" combined with Sanger sequencing, pathogenic gene diagnosis has been successfully completed for 24 large pedigree samples; using PCR amplification and Sanger sequencing, genetic diagnosis has been successfully completed for more than 30 pedigree samples. Providing pathogenic gene testing and genetic counseling for patients with hereditary ophthalmic diseases is not only conducive to clinical diagnosis of diseases, but also of great significance for clinical treatment, prognostic evaluation, eugenics, and the improvement of research standards in this field. 3) In 2007, with funding from the International Council of Ophthalmology (ICO), established the "Peking University Lilly Diabetes Eye Center." After considering the overall level of medical care in China, regional characteristics, and population distribution, a strategic approach was established to develop collaborative hospitals in remote, impoverished, and underdeveloped areas and to build a nationwide network for diabetes-related blindness prevention and treatment. To date, more than 30 collaborative sites have been established in the suburbs of Beijing and in provinces including Hebei, Shandong, Henan, Jilin, Inner Mongolia, Ningxia, Shanxi, Shaanxi, Zhejiang, and Liaoning, with standardized screening and clinical diagnosis and treatment protocols developed. This has made an important contribution to exploring an effective model for diabetes-related eye disease prevention and treatment for developing countries worldwide. 4) The Eye Injury Vitrectomy Study (EIVS), initiated in 1997, is currently the multicenter prospective cohort study with the largest number of severe eye injury cases, the most complete registration data, the longest mean follow-up duration, and the highest response rate internationally. To date, more than 2,000 cases have been registered. Awards 1996 Second Prize of Military Science and Technology Progress Award 1998 Third Prize of National Science and Technology Progress Award 1998 Third Prize of Military Science and Technology Progress Award 1998 Jiang Sichang Award Fund Prize 1998 First "Outstanding Student Scholarship of PLA Postgraduate Medical School" Award 2001 Second Prize of Military Science and Technology Progress Award 2007 Best Paper at the American Academy of Ophthalmology Annual Meeting 2009 First Prize of Clinical Medical Technology Innovation Award, Peking University Third Hospital 2010 One of the World's 100 Outstanding Physicians (The IBC Top 100 Health Professionals 2010) 2010 Armed Police Force Science and Technology Progress Award 2010 First Prize of Outstanding Management Project Award, Peking University Third Hospital 2010 Peking University Health Science Center Outstanding Talent Award Program 2011 China Outstanding Ophthalmologist Award 2013 Third Prize of High-Quality Service Advanced Collective Award, Peking University Third Hospital